Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/172664 
Authors: 
Year of Publication: 
2015
Citation: 
[Journal:] Intereconomics [ISSN:] 1613-964X [Volume:] 50 [Issue:] 4 [Publisher:] Springer [Place:] Heidelberg [Year:] 2015 [Pages:] 221-226
Publisher: 
Springer, Heidelberg
Abstract: 
Escalating healthcare expenditures and the need to ensure access to affordable medicine in both emerging and emerged economies are fuelling calls to contain the so-called evergreening practices of drug producers around the world. But such practices are the necessary outcome of a system that responds to market incentives and appears to be already sufficiently controlled by established patentability standards and policies that determine patent term extension. The key issues surrounding current trade disputes lie deeper. This article examines the link between technological advances and intellectual property rights in general and the presumably special case of drug supplies. It focuses on strategies for extending the market exclusivity for pharmaceuticals products and evaluates safeguards against such evergreening.
Persistent Identifier of the first edition: 
Document Type: 
Article
Document Version: 
Published Version

Files in This Item:
File
Size
160.43 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.